{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Class (Stereo):
CHEMICAL (RACEMIC)
Terbufibrol, an antihyperlipoproteinemic agent that blocks the hepatic cholesterol synthesis in a step between acetate and HMG-CoA (3-hydroxy-3-methylglutaryl-CoA). Information about the current use of this compound is not available.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Terdecamycin, an antibiotic that was studied on the pigs to treat dysentery. Information about the current use of this drug is not available.
Status:
Investigational
Source:
USAN:NIFLURIDIDE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Nifluridide, an experimental insecticide, is used for the control of sucking and biting insects such as Phthiraptera. Nifluridide was systemically active against Triatoma infestans on mice and Rhodnius prolixus on cattle.
Status:
Investigational
Source:
NCT00103519: Phase 2 Interventional Terminated Heart Failure, Congestive
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
3,5-Diiodothyropropionic acid (DITPA), a carboxylic acid analog with low metabolic activity, was observed to induce alpha-MHC mRNA in heart cell culture with EC50 approximately 5 x 10(-7) M. Zarion Pharmaceuticals was developing DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analogue, for the treatment of Allan-Herndon-Dudley syndrome. In May 2013, the US FDA granted DITPA orphan drug status for the treatment of Allan-Herndon-Dudley syndrome. However, development of DITPA for the treatment of Allan-Herndon-Dudley syndrome was discontinued.
Status:
Investigational
Source:
NCT00447629: Phase 1 Interventional Completed Diabetes Mellitus
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Indeglitazar is orally available peroxisome proliferator-activated receptor (PPAR) pan-agonist for all three PPAR subtypes alpha (α), delta (δ) and gamma patented by Plexxikon, Inc for metabolic disorders treatment. Indeglitazar is a full agonist of PPAR alpha but only a partial agonist of PPAR gamma and delta; this may provide a better side effect profile than full activators. The molecule shows impressive pharmaceutical properties (high oral bioavailability, the long half-life, etc.) as well as promising activity in mouse and rat models of diabetes (lower blood glucose, insulin, total cholesterol, triglycerides, free fatty acids, etc.). In contrast to other PPAR agonists, which sometimes cause weight gain, Indeglitazar also caused weight loss in rodent and primate models. Although Indeglitazar was advanced to phase 2 trials in collaboration with Wyeth, increasing concerns over the potential side effects of PPAR agonists have caused Wyeth to discontinue development of this compound
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Endomide is a central analeptic considered to be an antiparkinsonian agent.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Argimesna (also known as arginine 2-mercaptoethanesulfonate) is a sulfhydryl group-containing molecule, which has no effect on glutathione status or on the total thiol pool, but is an uroprotective agent. Argimesna was investigated for the prevention of haemorrhagic cystitis from ifosfamide (IFO), but these studies were discontinued
Status:
Investigational
Source:
INN:bensuldazic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Bensuldazic acid was used in veterinary as an antifungal agent.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ecenofloxacin (CFC-222), a fluoroquinolone, is a broad-spectrum antibacterial compound acting as a ype II DNA topoisomerase inhibitor. It exerts antibacterial activities against gram-positive, gram-negative, and anaerobic organisms. Ecenofloxacin development as an antibacterial agent has been discontinued.
Status:
Investigational
Source:
NCT02340325: Phase 1 Interventional Completed Cicatrix
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Kynurenic acid is a product of the normal metabolism of amino acid L-tryptophan which has been shown to have a neuroactive profile. It exhibits activity against NMDA receptors and Neuronal acetylcholine receptor subunit alpha-7. It has been investigated as a potential therapeutic compound and as a biomarker in a number of neurological disorders. Although Kenyruic acid exhibits a poor penetration of the blood-brain barrier, it remains to be of particular interest to those researching Schizophrenia.
